NY-ALEPH-FARMS
Aleph Farms, a cellular agriculture company designing new ways to grow quality animal products, today announced that Chef Marcus Samuelsson is joining the company as an investor, culinary advisor and launch partner. Through much of his rise to fame as the celebrity chef behind 13 restaurants around the world, a New York Times best-selling author and a TV personality, Samuelsson has been using his unique background to elevate diversity in the culinary world. As part of this designation, he will work closely with Aleph Farms as it approaches commercialization of Aleph Cuts, the world’s first cultivated steaks, providing a new take on steak.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005267/en/
Marcus Samuelsson x Didier Toubia (Credit: Noi Einav)
“Aleph Farms builds partnerships based on shared values. Like us, Chef Marcus believes in making a positive impact on our food systems with creativity, courage, and care,” said Didier Toubia, CEO and Co-Founder of Aleph Farms. “With his vast experience and focus on creating accessible and inclusive cuisine, Marcus’ insights and expertise are perfectly suited for developing and promoting Aleph Cuts to a wider global audience. Additionally, his reputation for celebrating food cultures that embrace high-quality ingredients aligns with our local approach to promoting food security in ways that can deliver broad social, economic and environmental benefits.”
In his role with Aleph Farms, Samuelsson will advise the company in a culinary capacity, including product development and go-to-market strategies. He has also invested in the company. Chef Marcus will work closely with Aleph Farms as it brings Aleph Cuts to Singapore and Israel later this year and to the United States next year, upon receiving regulatory approvals.
“It’s essential that we look for new ways to feed our planet sustainably, which is why I was attracted to the mission of Aleph Farms and being part, both as a chef and as an investor, in bringing delicious, cultivated meat to the table,” said Samuelsson. “Right now, it’s a pioneering movement and one that I think will only grow to be more important and increasingly commonplace in our lives. What once felt futuristic -- like electric cars -- soon becomes familiar. This is a game-changing moment in the industry to invest in the future, and I’m excited to partner with an innovative company like Aleph Farms.”
In his career, Samuelsson has won eight James Beard Foundation awards as a chef, author and TV personality, including for hosting No Passport Required on PBS. He appeared as an Iron Chef on Netflix’s hit Iron Chef: Quest for an Iron Legend. His restaurants worldwide include Red Rooster Harlem (New York City) and Red Rooster Overtown (Miami), MARCUS Montreal, Marcus B&P in Newark, Streetbird at Yankee Stadium, Marcus at Baha Mar Fish + Chop House in the Bahamas, the recently opened Hav & Mar in Chelsea (New York City) and Marcus Bar and Grille in Atlanta. As a committed philanthropist, Samuelsson is co-chair of Careers Through Culinary Arts Program (C-CAP), which helps underserved youth, and he converted Red Rooster Harlem and Red Rooster Overtown into community kitchens during the COVID-19 pandemic in partnership with World Central Kitchen.
Aleph Farms is working closely with regulatory agencies around the world as it prepares for the commercial launch of its first product under the Aleph Cuts brand, the Petit Steak, grown from non-modified cells of a premium Black Angus cow. As with all its products, there is no slaughter involved in production; instead, from a single fertilized egg, Aleph Farms can grow thousands of tons of cultivated meat, serving as part of a just and inclusive transition to sustainable and secure food systems. The company also has a “Whole Animal” approach by which it plans to produce different cuts of steak as well as other products based on animal cells, such as cultivated collagen, through additional proprietary capabilities.
About Aleph Farms
Aleph Farms is an Israel-based cellular agriculture company active in the food technology space. It designs new ways to grow quality animal products that improve sustainability, food security and animal welfare in our food systems. Founded in 2017, the company unveiled the world’s first cultivated thin-cut beef steak in 2018, the world’s first cultivated ribeye steak in 2021, and cultivated collagen in 2022. Under its product brand, Aleph Cuts, the company will launch its first product, the Petit Steak, grown from non-modified cells of a premium Black Angus cow. For its contributions to climate leadership including a net zero commitment made in 2020, it has received top accolades from the World Economic Forum and the United Nations.
For more information, follow Aleph Cuts on Instagram and Facebook, Aleph Farms on Twitter and LinkedIn, or visit www.aleph-farms.com. Access our press kit here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230607005267/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet13.6.2025 00:45:00 CEST | Press release
POD1UM-303/InterAACT 2 is the first and largest global Phase 3 trial evaluating a PD-1 inhibitor in combination with chemotherapy for the treatment of patients with advanced SCAC not previously treated with systemic chemotherapy The trial met its primary endpoint; treatment with retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel) resulted in clinically meaningful improvements in progression-free survival and overall survival In May 2025, the U.S. Food and Drug Administration (FDA) approved Zynyz® (retifanlimab-dlwr) in combination with carboplatin and paclitaxel and as a single agent for the treatment of advanced SCAC; submissions to other global regulatory agencies are also under review Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-base
Güntner Drives Group-Wide Innovation in 2024 Sustainability Report12.6.2025 21:30:00 CEST | Press release
Progress in natural refrigerants, water efficiency and circular economy underscores Güntner’s global impact Güntner, a global leader in refrigeration and heat exchange technology, today announced its featured role in the newly released 2024 A-HEAT Sustainability Report. The report outlines significant progress toward ambitious environmental goals—fueled by Güntner’s commitment to measurable, innovation-led sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612897493/en/ Güntner advances global sustainability goals with progress in natural refrigerants, water savings, and circular economy efforts. Working toward its 2030 sustainability targets, Güntner delivered significant achievements across key areas including natural refrigeration integration, water and energy efficiency and the development of circular economy solutions. These efforts reflect Güntner’s ongoing mission to make sustainability not just a goal,
Windsurf Launches First GPU Cluster in Germany, Expanding Secure Enterprise AI in Europe12.6.2025 20:45:00 CEST | Press release
Windsurf launches a GPU cluster in Germany, delivering 50% faster performance and secure access to European enterprises. Data residency ensures enterprise repositories stay within the EU, meeting stringent security requirements. Windsurf already supports 100+ European enterprise customers, highlighting strong demand for AI-powered development tools across EMEA. Windsurf, a leader in AI-powered software development, today announced its first GPU cluster in Germany, as product demand surges and the company expands performance capacity across the EU. With over 100 local enterprise customers already using Windsurf products, the new cluster marks the company’s first major international step in building scalable infrastructure for the European market. Located in Frankfurt, home to some of the world’s strictest data security laws, the cluster was a natural choice for Windsurf’s first deployment. This cluster was specifically designed to meet the unique security and performance requirements of
Xsolla Partners With Defold to Enable Seamless In-game Purchases for Web Developers12.6.2025 19:00:00 CEST | Press release
New SDK Integration Simplifies Monetization for Defold Developers Publishing on CrazyGames Ahead of Global Game Jam Xsolla, a leading global video game commerce company, announces a new strategic partnership with Defold, the cross-platform game engine trusted by professionals and indie developers worldwide. This collaboration introduces a seamless integration between Xsolla and Defold-built web games on CrazyGames, enabling developers to easily monetize their titles just in time for the CrazyGames x Defold Game Jam running June 13–15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612569206/en/ (Graphic: Xsolla) To address the complexity of in-game monetization, Xsolla and Defold have developed a new SDK that allows Defold developers to implement in-game purchasing functionality without the complex manual API setup required. With Xsolla’s sponsorship and support, this integration removes friction from the monetization jou
Pioneering Cancer Plasticity Atlas will Help Predict Response to Cancer Therapies12.6.2025 17:00:00 CEST | Press release
The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich today announced a collaboration to build the foundation of a single cell atlas, focused on understanding and elucidating cancer plasticity in response to therapies. The collaboration will catalyze an ambitious future phase to develop a cancer plasticity atlas encompassing hundreds of millions of cells. Utilizing novel organoid perturbation and Artificial Intelligence (AI) platforms, the aim is to create a comprehensive dataset to fuel foundational drug discovery models and cancer research. Dr. Mathew Garnett, Group Leader at the Sanger Institute, and Prof. Fabian Theis, Director of the Computational Health Center at Helmholtz Munich and Associate Faculty at the Sanger Institute, will be the principal investigators in the collaboration. Garnett’s research team has generated novel 3D organoid cultures that serve as highly scalable and functional cancer models with the ability to capt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom